Answers are grounded in this paper and cite their sources.
Examines a particular system for reporting clinical trials: the revised CONSORT system. Identifies its evolution and key components, indicating who may go on to use it, posting its key strengths, and concludes by identifying its outstanding limitations.
No takes yet. Share an insight, caveat, or question.
Alan Earl Slater (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: